Following the release of the Draft Sector Competitiveness Plan in July 2016, MTPConnect's judging panel selected 14 initial projects to receive funding of $7.4 million over the following two years, with matched sector funding of approximately $32 million.
The 2016 round of the MTPConnect Project Fund Program provided $7.4 million of funding for 14 national projects in the medtech, biotech and pharmaceutical (MTP) sector, that could leverage as much as $32 million in industry partner funds. The selected projects are set to deliver results on a national scale, have sector-wide impact, and are aligned with MTPConnect’s Sector Growth Priorities as defined in its draft Sector Competitiveness Plan. View the 2016 projects below and in the right-hand menu.
Expressions of Interest for the 2017 Project Fund Program will open on 3 July 2017. Sign up as a Network Affiliate to stay up to date for your chance to collaborate and help take the MTP sector to the next level.
2016 Project Snapshot
|Project Title||Description||Lead Applicant||Other Participants||Value|
|Industry Mentoring Network in STEM (IMNIS) program||Aiming to narrow the cultural gap that exists in Australia between business and academia through a program that will develop a national mentoring program linking PhD students with qualified industry mentors.||Australian Academy of Technology and Engineering||AusBiotech||Fund Contribution: $200,000 Partner contribution: $210,000 |
Project Value: $410,000
|The Actuator||To leverage Australia’s existing industry and research capabilities in the acceleration of new high-value, medical device technology development opportunities through a number of focused, 15-month actuator programs.||STC Australia||Artesian Venture Partners||Fund Contribution: $1,100,000 Partner contribution: $8,000,000 |
Project Value: $9,100,000
|Upgrade CSIRO Protein Production Platform||Aiming to upgrade the CSIRO (Clayton) protein production platform to human GMP capability for pilot-scale (<=200L) for a variety of expression systems (mammalian/yeast/ bacterial) as well as scale-up of cells. Will include a training program for post graduate study.||CSIRO||Monash University||Fund Contribution: $1,100,000 Partner contribution: $1,100,000 |
|BioFab3D@ACMD||Support for BioFab3D@ACMD, a robotics and biomedical engineering centre, embedded within a hospital. Researchers, clinicians, engineers and industry partners will work alongside each other with a vision to build biological structures such as organs, bones, brain, muscle, nerves and glands.||St Vincent’s Hospital (Melbourne) Limited||University of Melbourne, University of Wollongong, Swinburn University of Technology, RMIT University, Stryker Australia Pty Ltd||Fund Contribution: $1,100,000 Partner Contribution: $1,274,864 |
Project Value: $2,374,864
|Global Investment Program for Life Sciences||Comprehensive global investment program for the Australian life science sector – companies, investors and researchers.||AusBiotech Ltd||ASX; Dibbs Barker; WEBuchan; KPMG||Fund Contribution: $400,000 |
Partner contribution: $400,000
Project Value: $800,000
|ANDHealth||Creating an integrated ecosystem for the development & commercialisation of evidence-based digital health products.||ANDHealth||Murdoch Children’s Research Institute, Planet Innovation, Curve Tomorrow, Royal Children’s Hospital, HealthXL, GP2U Telehealth Pty Ltd, AusBiotech, RMIT University, Novartis Pharmaceuticals||Fund Contribution: $900,000 Partner contribution: $900,000 |
Project Value: $1,800,000
|Australian Centre for Regenerative Medicine||An Australian hub of Canada’s Commercialisation Centre for Regenerative Medicine (CCRM) will support the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies.||Monash University||CSIRO, CCRM Canada, Cell Therapies, St Vincent’s Institute of Medical Research, AusBiotech Ltd|| |
Fund Contribution: $200,000
Partner contribution: $500,000
Project Value: $700,000
|Hit ID platform||Build on a national framework to provide Australian drug discovery organisations access to a comprehensive Hit ID platform that includes: a fit for purpose drug discovery library (up to 300,000 compounds); an ultra-high throughput screening facility; fragment based drug design capability; and a state of the art software platform for in silico drug discovery.||Cancer Therapeutics CRC Pty Ltd (CTx)||UniQuest, Walter and Eliza Hall Institute (WEHI), Children’s Cancer Institute (CCI), Griffith University / Compounds Australia||Fund Contribution: $1,100,000 Partner contribution: $1,384,290 |
Project Value: $2,484,290
|Pilot Implementation of the Australasian Tele-Trial Model||COSA has developed a national guide for implementation of the Australasian Tele-Trial Model in consultation with clinical trial sponsors, clinicians, health administrators and regulatory bodies. This project will implement a feasible and effective tele-health strategy to increase access to clinical trials closer to home, while at the same time ensuring the proper conduct of cancer clinical trials.||Clinical Oncology Society of Australia (COSA)|| |
Rare Cancers Australia, Cancer Voices Australia, Australian Institute of Tropical Health and Medicine (AITHM), The Garvan Institute of Medical Research, The Walter and Eliza Hall Institute of Medical Research (WEHI), Icon Group, c/‐Icon Consolidated Holdings P/L, St John of God Hospital, Medicines Australia, AbbVie Pty Ltd, Janssen, Novartis Pharmaceuticals Australia Pty Ltd, Pfizer Australia Pty Ltd.
Fund Contribution: $115,000
Partner contribution: $230,000
Project Value: $345,000
|National Medical Device Partnering Program (NMDPP)||Initial scoping of the roll out of a National Medical Device Partnering Program (NMDPP) to bring together research, clinical and industry partners in a streamlined process for collaboration and product development.||Flinders University of South Australia||CSIRO, STC Australia, MTAA|| |
Fund Contribution: $150,000
Partner contribution: $150,000
Project Value: $300,000
|Project to assist in landscaping Australia’s vaccine research capabilities and relevant services for the use by the whole MTP sector in a searchable database. Australia’s first national Vaccine conference.||Vaxine Pty Ltd||Mylexa Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd|| |
Fund Contribution: $250,000
Partner contribution: $250,000
Project Value: $500,000
|The Bridge Program|| |
A consortium of 15 companies, universities and industry associations that aims to transfer practical skills on pharmaceutical commercialisation through online and residential training in drug discovery and development, and direct exposure to industry practitioners in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to the commercialising of medicines.
Queensland University of Technology (QUT)
Abbvie, Amgen, Australian Private Equity & Venture Capital Association Limited, Bristol-Myers Squibb Australia, Medical Research Commercialisation Fund, Boehringer Ingelheim, Celgene, CSL Limited, Janssen-Cilag, Macquarie University, Medicines Australia, Merck Sharp & Dohme (Australia), Mundipharma, Novartis Pharmaceuticals
Fund Contribution: $540,000
Partner contribution: $540,000
Project Value: $1,080,000
|Accelerating Australia|| |
A national consortium for translational medical technology and pharmaceuticals research and training. Small grant offered for scoping / development project on governance and national collaboration work.
Centre for Entrepreneurial Research and Innovation (CERI)
The University of Western Australia, Monash University, University of Sydney, SPARK Co-Lab Ltd, University of Technology Sydney, Proteomics International Limited, Orthocell Ltd, St John of God Healthcare, Avita Medical, Adelaide University, Murdoch University, Curtin University, Edith Cowan University, Harry Perkins Institute of Medical Research, Telethon Kids Institute, Lion’s Eye Institute, Ear Science Institute of Australia, Perron Institute for Neurological and Translational Science Limited
Fund Contribution: $150,000
Partner contribution: $150,000
Project Value: $300,000
|Biofabrication Institute|| |
Support for a biofabrication research centre located on a hospital campus utilising 3D digital scanning, modelling and advanced manufacturing technologies. Initially scanning and modelling ears for children with Microtia.
Queensland University of Technology
Hear and Say, Metro North Hospital and Health Service
Fund Contribution: $100,000
Partner contribution: $300,000
Project Value: $400,000
Clinical Trial Improvement Initiative
Clinical Trial Improvement Initiative - based on the a US model with a vision for a whole of sector approach to improve the quality, efficiency and impact of clinical trials.
|To be signed with 28 industry partners|| |
Fund Contribution: $370,000